Our state of art pre-clinical research
Our pre-clinical services for skin diseases and hair diseases have been designed to encompass the entire product development journey from low-cost investigative in vitro studies through to compound efficacy testing applying in vivo humanized mouse models. All our state-of-art pre-clinical research on skin diseases and hair diseases can be customized and developed according to our clients’ needs, for example in the field of cosmetology, dermatology, applications. Please do not hesitate to contact our scientific team for discussions over projects and assays development.
Additionally, the efficacy of screened candidates identified in pre-clinical research can be further investigated in our clinical hair trails unit. We are fully equipped with cutting edge techniques to conduct in-house studies and stand-alone projects.
For inquiries, please contact our Principal Scientist & Deputy General Manager, Dr. Marta Bertolini (email@example.com)
Human hair follicle organ culture
We apply different advanced microdissection techniques to isolate hair follicles from human scalp skin or follicular units. This allows us to efficiently culture either microdissected amputated/full-length hair follicle or an entire follicular unit.
Human skin organ culture
Our assays are based on the ex vivo culture of skin samples (also scalp skin) in serum-free medium and allows the investigation of skin responses after exposure to exogenous and endogenous modulators etc.
2D/3D in vitro cell model
We have a vast experience in isolating and culturing wide range of primary cell populations from healthy/diseased human skin and hair follicles. We provide rapid and cost-effective screening of test compounds for cosmeceutical, nutraceutical and therapeutic applications
Humanized mouse models
We have access to unique humanized mouse models that employ human skin xenotransplantation onto severe combined immune-deficient (SCID) mice to investigate the effect of test agents during therapeutic preclinical testing processes.